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1. Introduction 
Vasculitides comprise a heterogeneous group of autoimmune diseases sharing the common 
histopathologic feature of inflammation and fibrinoid necrosis of the blood vessel walls. 
Vasculitis features a wide variety of clinical manifestations depending on the localization 
and the size of the vessels involved, type of inflammatory infiltrate, and associated 
conditions making the diagnosis of specific forms of vasculitis difficult. The classification of 
the vasculitis remains a matter of controversy. Some classification systems have focused on 
the size of the vessels, while others have been based on histologic findings, yet an overlap of 
vessels of various sizes may occur, also the type of inflammatory infiltrate may change over 
time. Epidemiologic factors including; age, gender and ethnic background, patterns of organ 
affection, histopathologic and serologic features represent potential considerations while 
establishing the diagnosis and classification of vasculitis. The etiologic factors associated 
with the triggering of vascular endothelial injury and inflammations are quite variable with 
an unrecognized clear etiology in almost 50% of the cases. (Pipitone and Salvarni, 2006) 
The interest in infection related vasculitides has been boosted for the last two decades by the 
development of new molecular techniques. Currently, a causal relationship between 
hepatitis C virus (HCV) and vasculitis has been established. (Falk and Hoffman, 2007) 
Chronic hepatitis C viremia has been known to provoke a plethora of autoimmune 
syndromes, as well as nonspecific rheumatologic manifestations referred to as extra-hepatic 
manifestations of HCV. Such extra-hepatic syndromes have been reported in as much as 40-
90% of the chronic HCV infected patients, with a variable clinicopathological and serological 
spectrum that ranges between nonspecific serological abnormalities to manifest clinical 
disease with subsequent affection of multiple organs and systems. Established associations 
include; mixed cryoglobulinaemia (MC), complete or incomplete MC syndrome, porphyria 
cutanea tarda, significant associations include; autoimmune hepatitis, B cell non Hodgkin’s 
lymphoma, monoclonal gammopathies, possible association include; chronic polyarthritis, 
sicca syndrome, lung fibrosis, polyarteritis nodosa, poly/dermatomyositis, 
thyroiditis/thyroid cancer, diabetes mellitus, lichen planus, mooren corneal ulcers. (Kattab 
et al., 2010, Mohammed et al., 2010) 
2. Natural history and epidemiology of hepatitis C virus infection 
Hepatitis C virus infection is a major worldwide public health problem. The estimated 
global worldwide reservoir is almost 200 million or 3% of the global population. Hepatitis C 
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virus is a retrovirus, member of the genus hepacivirus of the flaviviridae family enveloped 
with a 9.6 kb single-stranded RNA genome. Six different viral genotypes of HCV have been 
identified. The sero-prevalence of each of these genotypes varies according to geographic 
distribution; genotype 1 has a worldwide distribution, genotype 2 being more common in 
western Africa and genotype 3 in the northern Indian subcontinent, with a sero-prevalence 
rate of less than 1% in Western Europe and 2-3% in some Mediterranean areas. Regional 
geographic heterogeneity in the sero-prevalence rate can exist within the same country (in 
the USA, genotype 1 infection is significantly more prevalent in the northeastern, 
southeastern and middlewestern areas than in patients from the west and south). African-
Americans are more likely to be infected with genotype 1 than Caucasians. Genotype 4 is 
predominant in the Middle East and Africa, genotype 4 is spreading in Western countries, 
especially among intravenous drug users. Genotype 5 is predominant in South Africa and 
genotype 6 in South-East Asia. Mixed cryoglobulinemia (MC), is considered the most highly 
associated and characteristic extrahepatic feature in HCV infection. (Mohammed et al., 2010) 
In HCV infected patients 30- 98% have cryoglobulinemia. Overt cryoglobulinaemic 
syndrome develops in 5–20% of patients. (Antonelli et al., 2009) The incidence of HCV 
infection in mixed cryoglobulinemia ranges from 40 to 90% and tests for viral genome 
concentrations in the cryoprecipitate might be as high as 1000 fold that of supernatant. (Ferri 
et al., 2002 a, Sansonno et al., 2007). 
3. Mixed cryoglobulinemia 
Mixed cryoglobulinemia (MC) is a chronic immune complex (IC) mediated systemic small 
vessel vasculitis, characterized by immune complex deposits (cryo-deposits) and frequent 
multiple organ involvement. A frequent synonym of this disease is “cryoglobulinemic 
vasculitis”, a term that focuses on the typical histo-pathological alterations responsible for 
muco-cutaneous and visceral involvement. (Agnello, 1995) The term cryoglobulinemia 
refers to the presence of a single component (monoclonal) or more (polyclonal) 
immunoglobulins. These immunoglobulins typically precipitate at temperatures below 37°C 
giving rise to high molecular weight aggregates and re-dissolve on rewarming. 
Cryoglobulins are found in small quantities in normal serum and are present in variable 
concentrations in many pathological conditions, including myeloproliferative disorders, 
autoimmune disorders and several infectious diseases. They are classified on the basis of 
their Ig component into: Type I cryoglobulins (10-15% of cryoglobulins) is comprised simply 
of monoclonal immunoglobulins, typically IgM but less frequently IgG, IgA, or serum light 
chains. Individuals with Type I cryos typically have a paraproteinemia (e.g., myeloma, 
Waldenstrom's macroglobulinemia). Type II cryoglobulins (50-60% of cryoglobulins) occurs 
when a monoclonal Ig M recognizes and binds to polyclonal IgG's, accordingly, type II cryos 
are typically IgM-IgG complexes .Type III cryoglobulins (30-40% of cryoglobulins) are 
composed of polyclonal Ig M that binds to polyclonal IgG. Type II & III cryoglobulinemia 
are referred to as “Mixed Cryoglobulinemia”, these are the types most commonly associated 
with hepatitis C. (Dammaco et al., 1997). The term essential cryoglobulinemia was used to 
describe cryoglobulinemia without identifiable underlying disease, currently it is clear that 
most of the patients with essential mixed cryoglobulinemia are chronically infected with 
HCV (Sansonno et al., 2007) Table 1 
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MM;multiple myeloma, WM; Waldenstrom macroglobulinemia, CLL; chronic lymphocytic leukemia, B-
NHL; B cell Non-Hodgkin’s Lymphoma 
Table 1. Classification of Cryoglobulins. (Ferri, 2008) 
3.1 Etio-pathogenesis of mixed cryoglobulinemia with HCV infection 
Combined Viral and host-related factors contribute to the pathogenesis of HCV-related MC 
and lymphoproliferative disorder. 
3.1.1 HCV infection of hepatocytes 
The HCV life cycle starts with virion attachment to its specific receptor on hepatocytes. 
Several candidate molecules have been suggested to play a role in the receptor complex, 
including tetraspanin CD81, the scavenger receptor BI (SR-BI), the adhesion molecules DC-
SIGN and L-SIGN, the low-density lipoprotein (LDL) receptor and recently, the tight 
junction components claudins (mainly CLDN-1,CLDN-6 and CLDN-9) have been identified 
as additional key factors for HCV infection. The HCV RNA genome serves as a template for 
viral replication and as a viral mRNA for viral production. In addition, the HCV enzymes-
NS2-3 and NS3-4A proteases, NS3 helicase and NS5BRdRp—are essential for HCV 
replication, and are therefore potential future therapeutic targets.The activity of liver disease 
associated with cryoglobulinemic vasculitis is usually mild  suggesting the existence of a 
state of immune tolerance between virus and host. At the same time the virus provokes a 
state of persistent high viremia necessary for circulating immune complex formation, 
essential for the activation of vasculitic inflammatory reaction. (Racanelli et al., 2001)  
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3.1.2 HCV and B lymphocytes 
It is believed that HCV infects B lymphocytes (BL) in the same way it infects hepatocytes 
due to the shared expression of CD81 receptors. HCV induces lowering of lymphocyte 
activation threshold leading to chronic lymphocyte stimulation and widespread 
autoantibody production. (Ferri et al., 2000) The proposed etio-pathogenic mechanisms in 
HCV- mixed cryoglobulinemia, involves the following:  
3.1.2.1-HCV-viral iymphotropism 
The characteristic genome variability and viral lymphotropism of HCV cause prolonged and 
sustained antigen stimulation of B cell compartment, mainly exerted by E2 protein  (highly 
variable region 1 HVR1) that allows distinguishing different, but strictly virus related 
genomic variants called quasispecies (Zignego and Brechot, 1999) and expresses B cell 
immunodominant epitopes involved in viral neutralization. Viral E2 region is able to 
directly interact with B-lymphocytes through tetraspanin CD 81 lowering the lymphocytes 
activation threshold (Pileri et al., 1998) with subsequent clonal expansion of the rheumatoid 
factor (RF) IgM/k producing lymphocytes (Agnello et al., 1992). The idiotypic similarities 
shared by mRFs from different patients with ttype II MC syndrome that correspond with a 
restricted set of rearranged immunoglobulin (Ig) genes that encode mRFs (IGHV1-69, 
IGHV3-23, and IGKV3-20 are associated with the WA CRI, IGHV3-7), suggesting that a 
specific antigen contributes to development of type II mixed cryoglobulinemia. Persistent 
and prolonged stimulation of B lymphocytes induces genetic modifications that play a key 
role in the evolution of lymphoproliferative disorders (LPD), passing from a physiologic 
polyclonal activation to a mono-oligo-clonal expansion characteristic of MC until the frank 
monoclonality of B cell lymphoma. In HCV related non-Hodgkin’s Lymphomas malignant 
monoclonal B cells produce an Ig M with rheumatoid factor activity and highly homologus 
to anti-E2 antibodies. (De Vita et al., 2000) 
3.1.2.2 Impaired apoptosis of B lymphocytes 
HCV-dependent gene translocation leads to Bcl-2 recombination, activation of this anti-
apoptotic protoncogene protects B lymphocyte from apoptosis triggering sustained B 
lymphocyte proliferation, autoantibody production, and oligoclonal monotypic 
lymphoproliferations with cells expressing oligo or monoclonal IgM sharing rheumatoid 
activity  (mixed cryoglobulins). Recent studies highlighted the existence of an elevated 
frequency of proto-oncogene bcl-2 rearrangement [t(14;18) translocation]  with altered bcl-
2/bax ratio in subjects affected by chronic HCV infection. High levels of Bcl-2 protein 
expression have been detected in bone-marrow and liver infiltrates of HCV infected patients 
with cryoglobulinemia upon histopatological analysis. (Zignego et al., 2002, Giannini et al., 
2008) 
3.1.2.3 B- Lymphocyte somatic hypermutations (SHM) 
Sequence analysis of rearranged Ig heavy chain genes within hepatic lymphoid infiltrates of 
patients with type II MC syndrome confirmed the presence of monoclonal or oligoclonal B-
cell populations with sustained  clonal somatic hypermutations (SHM) generating intra-
clonal diversity  in infilterates. SHM enhances antibody affinity for a particular antigen by 
introducing nucleotide substitutions within the immunoglobulin variable (IgV) genes of 
germinal center (GC) B-cells. Genetic mutation arising from aberrant SHM has been 
proposed to contribute to B-cell NHL (e.g mutation in 5’-untranslated region of proto-
www.intechopen.com
 
Hepatitis C Related Vasculitides 
 
305 
oncogenes like PIM-1, PAX-5, RhoH/TTF, and c-myc). The bcl-6 (B cell lymphoma-6) proto-
oncogene is a transcriptional repressor gene that prevents the terminal differentiation of 
mature B cells to plasma cells and promotes proliferation of B lymphocytes. Bcl-6 is recently 
recognized as another target of SHM in GC B- cells in patients with HCV infection. In vitro 
studies suggest that genetic mutations in HCV infected cells arise from induction of error 
prone DNA polymerase activity by HCV infection. (De Vita et al., 2002, Machida et al., 2004) 
3.1.3 Cytokines and soluble factors 
Cytokines play a central role in the immune response to viral agents. Increased intrahepatic 
levels of interleukin (IL)-2, IL-6 and IL-8 were demonstrated by RT-PCR in cirrhotic patients. 
(Napoli et al., 1994) In vitro studies showed that HCV, through the action of its NS5A 
protein, induces expression of Toll like receptors 4(TLR4), leading to enhanced IFN-ǃ and 
IL-6 production and secretion. Members of the TNF-superfamily appear to play a relevant 
role in B cell expansion during chronic HCV infection. The two new members of the TNF-
superfamily (B-lymphocyte stimulator-BLyS and APRIL- a proliferation inducing ligand) 
proved to play a crucial role in the control of humoral immunity. The binding of BLyS to its 
receptors (TACI and BLyS-R) induce strong B cells proliferation and extended survival via 
the strong activation of the antiapoptotic bcl-2 gene. Overexpression of BLyS in transgenic 
mice induced expansion and accumulation of mature B cells, high levels of serum IgG and 
IgM, and glomerulonephritis. BLyS, and its homologue APRIL, are now considered the 
main regulators of T-independent B-lymphocyte proliferation and autoimmunity. (Gross et 
al., 2000, Stein et al., 2002, Fabris et al., 2007, Sene et al., 2007) 
3.1.4 HCV infection and T cell regulatory function (T reg) 
The T-lymphocyte compartment was recently identified to acquire a distinct subset of 
lymphocytes with immune-regulatory properties named "regulatory T cells" (Treg). Treg. 
play a central role in modulating the immune response targeting infectious agents, in 
maintaining self-tolerance and lymphocyte homeostasis.(Sakaguchi, 2000) CD4+CD25+ T 
cells (T reg S) and "type 1 T regulatory cells" (Tr1) account for 5-10% of the CD4+ pool in 
normal subjects, they constitutively express CTLA-4 (CD152), and are anergic following in 
vitro TCR stimulation (partially reversed with high amounts of IL-2 and IL-15). The 
forkhead transcription factor Foxp3 is specifically expressed in CD4+CD25+ regulatory T 
cells and is required for their development and function. Several mutations within the 
Foxp3 gene alter CD4+CD25+ development, retroviral gene transfer of Foxp3 converts naive 
T cells toward a regulatory T cell phenotype similar to that of naturally occurring CD4+ 
regulatory T cells. "Type 1 T regulatory cells" (Tr1) are CD4+CD25-, which display a unique 
profile of cytokine production that is distinct from that of Th0, Th1 or Th2 cells and 
conversely to CD4+CD25+ they secrete high amounts of IL-10 and TGF-beta which in turn 
suppress naive and memory Th1 and Th2 responses, Such immune-dysregulation might 
contribute to chronic HCV viremia and cryoglobulin production. Patients with HCV-MC 
vasculitis were found to have a disturbed peripheral blood T cell repertoire, with a high 
frequency of T cell expansions. (Fontenot et al., 2003) 
A role for C1q auto-antibodies has been reported in HCV infected patients. C1q receptor is 
overexpressed at sites of inflammation. C1q-R exacerbates inflammation by generating 
vasoactive peptides from the complement system and bradykinin from the contact system. 
HCV core protein interacts directly with the globular domain of C1q protein (gC1q-R). 
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Engagement of circulating HCV core protein with gC1q-R on the surface of B lymphocytes 
provides the virus with a direct means of affecting host immunity. Recently, there is also 
evidence of an important role of vascular cell adhesion molecule-1 (VCAM-1) a molecule 
exclusively involved in mononuclear cell recruitment, in the pathogenesis of severe forms of 
HCV-MC vasculitis. (Kittlesen et al., 2000,  Kaplanski et al., 2005) 
3.1.5 Paracrine/soluble factors 
 Other paracrine/soluble factors might be involved in the pathogenesis of HCV-related MC. 
The analysis of global protein pool (proteomic analysis) in sera and peripheral blood 
mononuclear cells (PBMC) samples represents a promising approach for identify new tumor 
markers, identification of post-translational modifications, protein-protein interactions, 
protein level expression, protein networks. (Leak et al., 2002) Figure 1 
 
 
Fig. 1. Etiopathogenesis of HCV-Mixed Cryoglobulinemia  
3.2 Mechanism of cryoglobulin production 
The intrinsic mechanism by which HCV promotes cryoglobulin production remains unclear. 
It is postulated that upon initial antigenic stimulation, it is the interaction between HCV and 
lymphocytes that directly modulates B and T cell functions. Initial polyclonal activation and 
expansion of CD5þ cells (major source of IgM RF) occurs in type III mixed 
cryoglobulinemia. This is followed by the emergence of a single dominant clone of B 
lymphocytes with the production of monoclonal IgM RF. This clonal heterogeneity of IgM 
rheumatoid factor defines type II-type III variants which is considered a transitional stage in 
the switch between type III to type II MC. In HCV infection mixed cryoglobulins are 
predominantly type II cryoglobulins. (Sasso, 2000, Newkirk, 2002) Cryoglobulins interact 
with HCV forming immune complexes composed of HCV, anti-HCV polyclonal IgG and 
monoclonal IgM sharing Rheumatoid factor (RF) activity.  
The presence of IgM RF in this megacomplex (cryoprecipitate complex) provides an obstacle to 
the incorporation of complement factor C3b into this complex. The incorporation of this C3b is 
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important as it allows binding of the immune complex to CR1 erthrocyte surface receptor 
required for immune complex neutralization. Thus this immune complex escapes 
neutralization by erythrocyte. HCV induces abnormalities in the biogenesis of lysosomal 
enzymes impairing the capacity of monocytes to digest engulfed immune complexes a 
phenomena described as “phagocyte blockade”. Failure of neutralization promotes the cryo-
complex to circulate freely in an abundant form saturating the phagocyte ability to remove 
such immune complexes from the blood and creating a state of mixed cryoglobulinemia. 
This complex can easily deposit in tissues and promote inflammatory cascade. (Ferri et al., 
2002 a, Sasso, 2000) The exact mechanisms leading to cryoprecipitation remain unclear. 
Different hypotheses have been proposed to explain this phenomenon, namely: (1) 
structural modification of the variable portions of Ig heavy (H) and light (L) chains; (2) a 
reduced concentration of sialic acid; (3) reduced amounts of galactose in the Fc portion of 
the Ig4; and (4) the presence of N-linked glycosylation sites in the CH3 domain as a result of 
somatic Ig mutations during autoimmune responses. (5) Specific interactions between the 
IgM cryoprecipitable rheumatoid factor (RF) and the Fc portion of IgG, the corresponding 
autoantigen. (6) Occupancy of the Fc portion of IgG by IgM molecules is probably a major 
factor in the functional properties of immune complexes (ICs). They are large ICs known to 
be poor acceptors of C3 and C4, and deplete complement rather than fix it. Precipitation of 
these cryocomplex in the small blood vessels leads to cryoglobulinemic vasculitis. (Curry et 
al., 2003, Ferri, 2008, Saadoun et al., 2007)  
3.3 Pathology in cryoglobulinemic vasculitis  
The classic pathology in cryoglobulinemic vasculitis is leukocytoclastic vasculitis, a form of 
immune mediated small vessel vasculitis with immune complexes deposit in the walls of 
small blood vessels. This is associated with activation of the complement cascade and the 
production of C5a (a neutrophil polymorph chemotactant). The resultant polymorph influx 
is associated with release of lysosomal enzymes, including elastases and collagenases, 
resulting in blood vessel wall damage, fibrin deposition and the release of red blood cells 
into the perivenular connective tissue (palpable purpura). Thrombosis with epidermal 
ischemic damage is not uncommon. High levels of circulating immune complexes which 
correlated with vasculitic lesions can be detected. Immunoglobulins and complement were 
identified in vitro, by immunofluorescence or immune-peroxidase techniques, visualized 
ultra-structurally as clumps of electron-dense material, usually within the basement 
membrane between endothelial cells and pericytes of post-capillary venules. Examination of 
apparently uninvolved skin from patients with leukocytoclastic vasculitis sometimes shows 
immunoglobulin and complement within the walls of dermal blood vessels. The findings of 
immunofluorescence studies vary according to the age of the lesion. Immunoglobulins have 
been described in up to 81% of patients in early lesions, C3 and Ig M predominate, in fully 
developed lesions there is predominance of fibrinogen and Ig G and in late lesions 
fibrinogen and C3. (Stone, 2009)  
4. Cryoglobulinemic vasculitis, the disease 
HCV-related mixed cryoglobulinemia represents a form of small vessel vasculitis which 
manifests by a variety of autoimmune manifestations referred to as cryoglobulinemic 
syndrome. The cryoglobulinemic syndrome typically presents by Meltzer triad which is a 
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triad of purpura, weakness, arthralgia and/or arthritis, thereafter, a series of multisystem 
pathologies follow. Meltzer triad has been reported in 25-30% of patients with mixed 
cryoglobulinemia. Widespread vasculitis involving medium-small sized arteries, capillaries 
and venules with multiple organ involvement may develop in a small proportion of patients 
(Meltzer et al., 1996, Ferri et al., 2004, Ferri et al., 2006).  
4.1 Frequency 
4.1.1 United states  
The prevalence of essential mixed cryoglobulinemia is reported as approximately 1:100,000. 
However, the exact prevalence of HCV related MC depends upon the geographic 
heterogenity of HCV infection. 
4.1.2 International 
The prevalence of mixed cryoglobulinemia is related to the endemic presence and 
geographic heterogeneity of HCV infection. The disease is more common in Southern 
Europe than in Northern Europe or Northern America. The incidence of HCV infection in 
mixed cryoglobulinemia in the Mediterranean Basin is 90%. A growing incidence of HCV-
related MC is observed especially in developing countries. HCV is endemic in some 
countries of the middleeast. Egypt has an exceptionally high prevalence of HCV infection 
estimated to be between 10% and 15% of its’ 75 million population. The annual infection rate 
is more than 70, 000 new cases of which at least 35, 000 would have chronic hepatitis C, with 
viral genotype 4  the predominant genotype being isolated in up to 91% of HCV infected 
persons in Egypt. In a recent research conducted on 306 Egyptian patients with chronic 
HCV infection the prevalence of MC amongst other extrahepatic manifestation was 0.7%.  
4.2 Predisposing factors 
4.2.1 Race 
Mixed cryoglobulinemia doesn’t appear to have any specific racial predilection. 
4.2.2Age 
Reported age range between 30-70 years (mean age reported 42-52 years). 
4.2.3 Hormonal factors 
The female-to-male ratio in mixed cryoglobulinemia is 3:1, female sex is considered one of 
the risk factors for developing extra-hepatic manifestations. Recent studies revealed an 
association between female gender and the presence of certain manifestations including 
fibromyalgia, cryoglobulinemic syndrome, autoimmune hemolytic anemia and arthritis. 
(Mohammed et al., 2010, Stefanova Petrova et al., 2007)  
4.2.4 Genetic factors 
HLA-B8 and DR3 may be considered risk factors for HCV-related MC in addition to 
cirrhosis. Recent data suggest that the HLA- phenotype B8 and DR3 are associated with 
increased risk of developing mixed cryoglobulinemia in HCV infected patients with the 
strongest association being with HLA-B8. Patients exhibiting the B8-DR3 phenotype may 
carry the C4A deletion, which might contribute to the low C4 levels measured in a 
proportion of MC patients in addition to complement consumption by the disease process 
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itself. Preliminary results on C4 allotyping in MC patients showed an increased frequency of 
C4AQ0 phenotype, thus suggesting a possible role of class III molecules in increasing the 
susceptibility to MC in HCV patients. (Ferri, 2008, Lenzi et al., 1998) 
4.3 Criteria for the classification of mixed cryoglobulinemia 
In 1989, the Italian group for the study of cryoglobulinemia has proposed preliminary 
criteria for the classification of MC. A revised version of these criteria including clinic-
pathological and serological findings has been recently proposed, Criteria displayed in 
Table 2. (Ferri, 2008) 
 




















HCV+ or HBV+: markers of hepatitis C virus or hepatitis B virus infection (anti-HCV ±HCV RNA; 
HBV DNA or HBV surface antigen). 
“Definite” mixed cryoglobulinaemia syndrome: 
(a) Serum mixed cryoglobulins (±low C4) + purpura + leucocytoclastic vasculitis. 
(b) Serum mixed cryoglobulins (±low C4) + 2 minor clinical symptoms + 2 minor 
serological/pathological findings. 
“Incomplete” or “possible” mixed cryoglobulinaemia syndrome: 
(a) Mixed cryoglobulins or low C4 + 1 minor clinical symptom + 1 minor serological ±pathological 
findings. 
(b) Purpura and/or leucocytoclastic vasculitis + 1 minor clinical symptom + 1 minor serological 
±pathological findings. 
(c) Two minor clinical symptoms + 2 minor serological ± pathological findings. 
“Essential” or “secondary” mixed cryoglobulinaemia: 
Absence or presence of well known disorders (infectious, immunological, or neoplastic) at the time 
of the diagnosis. 
Table 2. Classification Criteria for Mixed Cryoglobulinemia  
4.4 Clinical picture of cryoglobulinemic vasculitis and related autoimmune syndromes  
4.4.1 Skin involvement 
Skin is the most commonly affected target organ in cryoglobulinemic vasculitis. The classical 
pattern in mixed cryoglobulinemia is cutaneous leukocytoclastic necrotizing vasculitis. (lee 
et al., 1998, Leon et al., 2002) 
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The most commonly reported clinical feature of MC is palpable purpura. Palpable purpura 
manifests in as much as 70-90% of patients. Lesions are typically seen on the lower legs 
because of hydrostasis and blood vessel flow sludging, lesions might extend to the 
abdominal wall and less frequently to the trunk and upper limbs. The purpuric rash might 
acquire a petechial, papular, seldom necrotic aspect, and it can be compounded to 
erythematous maculae and dermal nodules. Lesions might be associated with other 
dermatological symptoms like upper malleolar ulcers as well as urticarial vasculitis. 
(Antonelli et al., 2009)  
 
  
 a                                    b                                           c                                         d 
Fig. 2. a- Cutaneous leukocytoclastic vasculitis in mixed cryoglobulinemia patient, b- 
Palpable purpura with cutaneous leukocytoclastic vascultitis in a female patient with 
cryoglobulinemic syndrome. c- Nuclear dust associated with a perivascular neutrophilic 
infiltrate. d- Leukocytoclastic vasculitis (black arrows point to small blood vessels in the 
subcutaneous tissue with perivascular leukocytes).  
Histopathological examination: Skin biopsy is optimally performed by 24-48 hours after the 
appearance of the lesion. Biopsies should be obtained from non-ulcerated site. Light 
microscopic examination reveals that the cellular infilterate is composed of a combination of 
neutrophils and lymphocytes with a predominance of one cell type or another. Lymphocyte 
infilterates are seen in specimens from either new (<12 hours) or old (>48 hours) lesions. The 
typical histolopathologic features from cutaneous vasculitic lesions involve the disruption of 
blood vessels architecture by an inflammatory infilterate in and around the vessel walls. 
Endothelial swelling and proliferation, leukocytoclasis (characteristic degranulation of 
neutrophils with the production of nuclear dust), might be accompanied by extravasation of 
erythrocytes. The severity of the histo-pathological changes in the cutaneous lesions of 
leukocytoclastic vasculitis does not predict extra-cutaneous involvement. Direct 
immunofluorescence (if sufficient lesions exist, separate biopsies are recommended for 
histology and DIF). DIF helps to differentiate pauci-immune and immune complex 
mediated vasculitis. In DIF frozen sections are incubated with flourescein labeled anti 
human immunoglobulin (Ig) IgG, IgM, IgA and complement 3. The staining pattern of these 
immune-reactants provides insight into the diagnosis, the pathophysiology of the lesions 
and the autoantibody components of the immune complexes. (Stone, 2009, Antonelli et al., 
2009) 
Other cutaneous features of HCV-MC include; Ischemic necrosis (0-20%), Livedoid 
vasculitis (14%), cold-induced urticaria (10%), hyperkeratotic spicules in areas exposed to 
cold, scarring of tip of nose, pinnae, fingertips, and toes, raynaud’s phenomenon, 
acrocyanosis which might evolve to digital ulceration might occur (Saadoun et al., 2007), 
and nail-fold capillary abnormalities. (Antonelli et al., 2009, Ferri, 2008) 
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4.4.2 Musculoskeletal involvement 
Musculoskeletal complaints are present in as much as 70-80% of the cryoglobulinemic 
patients, with arthralgia in 40-80% of cases, frank arthritis occurs in less common < 10% of 
cases. Joint affection in MC is usually bilateral, symmetrical, non-deforming, affecting 
mainly large articulations, knees and hands, less commonly elbows and ankles with no 
radiographic evidences of joint destruction in HCV-MC related arthritis. RF activity is 
present in 70-80% of MC patients. Joint involvement can occur in the absence of RF 
seropositivity. (Lee et al., 1998, Mohammed et al., 2010) Antibodies to citrullinated C peptide 
(highly specific for rheumatoid arthritis) usually aren’t significantly present. Myalgias, 
fibromyalgia, weakness and chronic fatigue are more frequent in cryoglobulin-positive than 
in cryoglobulin-negative HCV patients with recent evidences revealing higher prevalence of 
fibromyalgia and chronic fatigue syndrome with elevated fatigue score in HCV female 
patients. The elevated fatigue score is probably related to an increase in serum leptin levels 
which might interact with serotonin neurotransmission. Polymyositis is not uncommon. 
(Sene et al., 2006, Wener et al., 2004) 
4.4.3 Neurological involvement 
Neurological involvement in HCV-mixed cryoglobulinemia commonly presents by 
vasculitic peripheral neuropathy (subacute, chronic or acute on top of chronic). The pattern 
of affection ranges from pure sensory axonal neuropathy to mononeuritis multiplex. The 
most frequently described form is distal sensory or sensory motor polyneuropathy. Motor 
deficit is inconsistent, predominantly affecting the lower limbs appearing after sensory 
affection. The sensory involvement is usually bilateral commonly asymmetrical, with 
parasthesias and burning pain having characteristic nocturnal exacerbation. 
Polyneuropathies represent 40-70% of mixed cryoglobulinemic neuropathy, whereas 
mononeuritis multiplex represents 30-55% of cases. Nerve conduction studies show 
predominantly axonal neuropathy affecting mainly the sensory nerves. Nerve biopsies 
reveal axonal degeneration, differential fascicular loss of axons, signs of demyelination and 
small vessel vasculitis with mononuclear cell infilterate in the perivascular area, HCV-RNA 
was found in epineural cells by reverse transcriptase polymerase chain reaction (RT-PCR). 
(Authier et al., 2003) Central nervous system involvement in patients with HCV-associated 
vasculitis is rare. (Dawson et al., 1999) Clinical presentations might be in the form of 
transient ischemic attacks, stroke, progressive reversible ischemic neurological deficits, 
lacunar infarcts, pseudotumor cerebri or encephalopathic syndrome. Magnetic resonance 
imaging studies are consistent with ischemic injury, with either small lesions of the 
periventricular white matter and the cerebral trunk or extensive supra and infra-tentorial 
white matter lesions diagnostic of cerebral vasculitis predominantly small sized vessel 
vasculitis. Neurocognitive impairment and Guillian-Barre syndrome can exist. (Casato et al., 
2005, Heckmann et al., 1992) 
4.4.4 Renal Involvement in HCV-mixed cryoglobulinemia syndrome: 
Renal involvement in HCV-infected patients occurs in 10-60% of cases (figure 6). The most 
commonly repoted form is cryoglobulinemic membranoproliferative glomerulonephritis. 
Less common forms of renal involvement include; non-cryoglobulinemic 
membranoproliferative glomerulonephritis, Ig A nephropathy, postinfectious 
glomerulonephritis, membranous nephropathy, thrombotic microangiopathies, focal and 
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segmental glomerulosclerosis, fibrillary or immunotactoid glomerulopathy. 
Cryoglobulinemia is present in almost 100% of patients with HCV- nephropathy. Renal 
involvement in HCV-MC is an immune complex mediated nephropathy (deposition in the 
glomerulus of immune-complexes made by the HCV antigen, anti-HCV Ig G antibodies, 
and a rheumatoid factor, which is an IgM kappa), usually in the form of type I membrano-
proliferative glomerulonephritis (MPGN). Such pattern of organ involvement severely 
affects the prognosis and survival of patients with HCV-mixed cryoglobulinemia.  Renal 
disease in most cases, is a subsequent event to the cutaneous lesions (purpura), and might 
be associated with other extrahepatic manifestations like arthralgia and neuropathy. The 
commonest renal manifestation is asymptomatic proteinuria with microscopic hematuria, 
renal function is usually normal. In one quarter of patients there is nephritic syndrome, with 
macroscopic hematuria, proteinuria, hypertension, and increased serum creatinine. 
Hypertension develops in almost 80% of cases and often difficult to control. Occasionally, 
there is proteinuria in nephrotic range. The renal course of mixed cryoglobulinemia is 
variable; glomerular lesions usually have a more benign course than idiopathic 
membranoproliferative GN. Moderate renal insufficiency occurs in up to 50% of patients. 
Chronic renal failure develops years after the onset in approximately 10% of cases, oliguric 
or anuric renal failure develops in <5% of patients. There is hypo-complementemia in most 
of cases, but usually it is more marked for C4, with C3 slightly decreased or normal. (Garini 
et al., 2005, Kamar et al., 2006)  
 
 
Fig. 3. Cryoglobulinemic glomerulonephritis with membranoproliferative and mesangial 
proliferative features. Strongly PAS-positive small cryoglobulin plugs are present within 
capillary loops. In the setting of subacute cryoglobulinemic glomerulonephritis, 
inflammatory cells can be present within the glomerulus. (periodic acid-Schiff stain original 
magnification x200) 
Histopathological examination reveals glomerular hypercellularity predominantly by 
leukocytes and monocytes (different to idiopathic MPGN in which hypercellularity is 
mainly by mesangial and endothelial cells). Capillary walls show similar characteristics to 
those of idiopathic MPGN: double contours, “tram-tracking” aspect, duplication of the 
glomerular basement membrane and cells interposition in the subendothelial space (mainly 
monocytes). Usually there are nodular, eosinophilic, hyaline, homogeneous deposits 
occupying some glomerular capillary lumina: intraluminal thrombi; when present are 
highly suggestive of the disease. Crescents are not frequent. In few patients there is 
mesangial hypercellularity and sclerosis signifying chronicity with progressive organ 
damage. Immunofluorescence: There are parietal subendothelial deposits of IgG and IgM, 
usually accompanied by C3 and C4, with a variable intensity. Intraluminal thrombi are 
strongly positive for IgG and IgM demonstrating their origin in immune complexes. 
Staining for IgG and IgM may be present in mesangium, arterial walls, and arterioles. When 
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there is a monoclonal component (in type II cryoglobulinemia) the monoclonal origin can be 
demonstrated (usually kappa light chain). Electron microscopy: Glomerular lesions are very 
similar to those found in type I MPGN, but in cryoglobulinemia deposits are 
characteristically: organized, fibrillary or microtubular, with a distinctive substructure; there 
is a combination of curved cylinders arranged in pairs and annular structures in the 
subendothelial space. The cells that interpose in the subendothelial space (between the 
original GBM and the new synthesized membrane, or between GBM and endothelial cell) 
are in their majority monocytes (in idiopathic MPGN, mesangial cells occupy this space). 
(Garini et al., 2004)  
4.4.5 Sicca syndrome  
Symptomatic xerophthalmia and xerostomia occurs in 10-53% of HCV infected patients, the 
classical definite picture of S jogren’s syndrome is less commonly encountered in HCV-MC 
patients. In a recent study, serological screening of 1309 patients with Sjogren’s syndrome 
for HCV seropositivity showed 156 patients (12%) to be seropositive for HCV. In HCV 
related sicca syndrome, xerostomia was found more abundant than xerophthalmia. (8) Sicca 
syndrome with HCV-MC represents a form of lymphocytic sialadenitis, the mechanism of 
damage to the salivary epithelial cells might be due to; either direct viral sialotropism (virus 
secreted in the saliva) or indirect immune mediated inflammatory process. Unlike patients 
with primary Sjogren’s syndrome in patients with HCV-MC related Sjogren’s syndrome, 
serological markers for MC are usually present including low complement 4, rheumatoid 
factor seropositivity and detectable mixed cryoglobulins. Salivary gland biopsy shows 
pericapillary and non-pericanalary lymphocytic infilterate with lack of glandular canal 
damage. In patients with HCV related sialadenitis the prevalence of anti-SSA and anti-SSB 
antibodies were nearly 20%. (Doeffoel- Hantz et al., 2005, Ramos-Casals et al., 2001) 
4.4.6 Lung involvement 
Pulmonary involvement is more common in cryoglobulinemic HCV-infected patients 
compared to non-cryoglobulinemic patients. Pulmonary involvement is mild and mostly in 
the form of interstitial lung disease. The disease is usually clinically inert, except for some 
patients who present with cough, moderate exertional dyspnea and a minimal decrease in 
pulmonary function tests. Pleural effusion and alveolitis with alveolar hemorrhage, 
hemoptysis, severe acute lung insult with acute respiratory distress might develop in HCV-
MC. The condition is usually fatal and is mostly due to diffuse pulmonary vasculitis 
(autopsy disclosed pulmonary perivascular localization of IgG and IgM with immune 
complex materials containing IgM (kappa) and IgG occluding the pulmonary vessels in 
these patients (Ferri et al., 1997, Okutan et al., 2004, Suzuki et al., 2003). 
4.4.7 Gastrointestinal tract involvement 
Gastrointestinal involvement occurs in 2-22% of cases. Mesenteric vasculitis with abdominal 
pain, acute abdomen and even gastrointestinal bleeding might occur in HCV 
cryoglobulinemic vasculitis. Liver damage is common, over 50% of patients show signs of 
mild to moderate chronic hepatitis at diagnosis. Liver involvement is characterized by 
abnormally increased liver enzymes with or without echographic and/or histological 
features of chronic hepatitis, cirrhosis, or hepatocellular carcinoma. Late evolution into overt 
cirrhosis occurs in 25% of cases. Cryoglobulins are a prognostic indicator for increased risk 
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of cirrhosis in patients with chronic hepatitis C. Splenomegaly might coexist. (Kayali et al., 
2003, Remoroza and Bonkovsky, 2003) 
3.4.8 Cardiovascular involvement 
Patterns of cardiovascular involvement in HCV-MC include: mitral valvular damage with 
mitral regurge, coronary vasculitis complicated by myocardial infarction, pericarditis, 
congestive heart failure and hypertrophic cardiomyopathy. Arterial thrombosis reported in 
1%. (Antonelli et al., 2009) 
4.4.9 Ocular 
Retinopathy with cotton-wool spots, hemorrhages and arteriolar occlusion on fundus 
examination can occur in HCV patients with cryoglobulinemia, but rather a frequent 
complication of interferon therapy than HCV related small vessel vasculitis, uveitis is rare. 
Mooren’s ulcer is a rapidly progressive, painful ulceration of the cornea that might occur. The 
diagnosis of Mooren’s ulcer is a diagnosis of exclusion. (Remoroza and Bonkovsky, 2003) 
4.4.10 Endocrine system 
Some endocrinological disorders are significantly more frequent in HCV-MC patients 
compared to the general population. The most common endocrinal disorders are the thyroid 
disorders including; autoimmune thyroiditis, subclinical hypothyroidism, thyroid cancer 
with high prevalence of anti-thyroperioxidase antibody and antithyroglobulin antibody. 
Hyperthyroidism is less frequent, generally as reversible complication of interferon 
treatment. Type 2 diabetes is another frequent endocrinal disorder in cryoglobulin-positive 
than in cryoglobulin-negative patients. The raised prevalence of type 2 diabetes in HCV-
patients with mixed cryoglobulinemia is attributed to an immune-mediated mechanism 
(127). Insulin resistance mediated by proinflammatory cytokines, rather than a deficit in 
insulin secretion, is propably the primary pathogenic mechanism involved in the 
development of type 2 diabetes in HCV infection. Erectile dysfunction is another disorder in 
male patients with HCV-MC attributable to hormonal and/or neuro-vascular alterations. 
(Antonelli et al., 2004 a&b, Ferri et al., 2002,b) 
4.4.11 Hematological abnormalities 
Anemia of chronic disease and thrombocytopenia are amongst the commonly reported 
hematololgical abnormalities in HCV-patients with cryoglobulinemia. The proposed 
pathological mechanisms in HCV related thrombocytopenia involved; platelet sequestration 
and destruction in the spleen, along with low thrombopoetin production and direct viral 
infection of the megakariocytes with immune mediated platelet destruction. (De Almeida et 
al., 2004, Doi et al., 2002, Giannini et al., 2002, Jiang et al., 2002). Autoimmune hemolytic 
anemia has been reported in female patients with cryoglobulinemic syndrome (8), 
Leukocytosis, an elevated erythrocyte sedimentation rate (ESR) and an elevated C-reactive 
protein level are common findings in most types of vasculitis. The auto-antibodies seen in 
patients with HCV infection resemble those seen in chronic viral infections - the 
autoantibody titers are low, frequently found during the clinical course of cryoglobulinemia, 
however, not essentially associated with typical autoimmune disease. Serological 
abnormalities in HCV-MC involve positive antinuclear antibodies (ANA), antismooth 
muscle antibodies (ASMA), anti-neutrophil cytoplasmic antibodies (ANCA), and anti-
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cardiolipin autoantibodies. The prevalence of ANA and ASMA ranges from 4.4% to 41% 
and 7% to 66% respectively usually with low titre ≤ 1/160. HCV core particles concentrated 
in the cryoprecipitate provoke an interaction between the cryoglobulins, endothelial cells 
and neutrophil granulocytes. A positive ANCA has been found in <5-10% of patients with 
HCV-associated mixed cryoglobulinemia with proteinase 3 and dihydrolipoamine 
dehydrogenase as the main anti-neutrophil cytoplasmic antigens in patients with HCV-MC. 
HCV patients with ANCA had a higher prevalence of skin involvement, anemia, abnormal 
liver function tests and elevated alpha feto-protein levels. Anti-cardiolipin antibodies occur 
in 3.3% to 22% of HCV patients, with higher frequency in patients with HCV-associated 
cryoglobulinemia yet insignificant being anti-b2-glicoprotein independent. (Cacoub et al., 
1997, Lamprecht et al., 2003, Ordi-Ros et al., 2000, Yee et al., 2004, Wu et al., 2002 )  
4.4.12 Neoplastic disorders 
Mixed cryoglobulinemia syndrome is considered as a pre-neopastic syndrome that features 
a cross road between virus related autoimmune syndromes and virus associated 
malignancies (B cell lymphoma, hepatocellular carcinoma). B-cell lymphoma is the most 
frequent neoplastic manifestation complicating mixed cryoglobulinemia that presents late in 
the course of the disease. (Cacoub et al., 2000) Neoplasia is attributed to sustained 
peripheral B-lymphocyte expansion with significantly persistent lymphoid infiltrates that 
remain unmodified for years in the liver and bone marrow of MC patients. Such infiltrates 
are considered as "early lymphomas", and are given the nomenoclature "monotypic 
lymphoproliferative disorder of undetermined significance (MLDUS)". Type II MC-related 
MLDUS has the highest incidence in the same geographic areas with high prevalence of 
HCV infection. The onset of malignant lymphoma is usually 5-10 years after disease 
diagnosis, with a reported incidence of less than 10% in some patients to as high as 40% in 
others. Overt lymphoid tumors develop in about 10% of cases. A sudden decrease or 
disappearance of serum cryoglobulins and RF with abnormally high levels of C4, are 
presenting symptoms of complicating B-cell malignancy. Other neoplastic manifestations, 
i.e. hepatocellular carcinoma or papillary thyroid cancer, are less frequently observed (Ferri 
et al., 2002, Matsuo et al., 2004, Quartuccio et al., 2007).  
4.4.13 Other disease related features 
Constitutional symptoms like fever, fatigue, anorexia, weight loss, amongst other immune 
mediated HCV related extra-hepatic manifestations including: Porphyria cutanea tarda, 
Lichen planus, pancreatitis, aplastic anaemia, systemic lupus erythematosus, CREST 
syndrome, and waldenstrom’s macroglobulinemia might exist. (Ferri et al., 2002 a, Ferri et 
al., 2000) 
5. HCV and polyarteritis nodosa PAN (medium sized vessel vasculitis) 
Despite that polyarteritis nodosa is more commonly reported in patients with hepatitis B 
viremia, yet medium sized vessels inflammation can occur in patients with chronic HCV 
infection featuring a polyarthritis nodosa pattern of vasculitis. PAN can occur in 
cryoglobulinemic as well as non cryoglobulinemic HCV patients. HCV related PAN 
displays a more severe and acute clinical presentation with more frequent fever and weight 
loss, severe hypertension, gastrointestinal tract involvement, severe acute sensory-motor 
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multifocal mononeuropathy, kidney and liver microaneurysms and elevated acute phase 
reactants levels. Cases of mesenteric vasculitis with stenosis and narrowing of the superior 
mesenteric vessels and reno-vascular micro-aneurysm with renal cortical infarcts have been 
described in HCV patients having purpuric eruptions, hypertension and abdominal pain. 
Such lesions resolved with antiviral therapy and prednisolone, supporting the possible 
etiopathogenic role of chronic HCV infection. Another case with vasculitic mucosal colonic 
ulceration with massive hematochezia, purpura, abdominal discomfort, pulmonary 
infilterate and acute renal failure was described in a female patient with chronic HCV 
infection and negative for cryoglobulinemia, colonic biopsy showed evidence of fibrinoid 
necrotizing arteritis diagnosing a case of HCV related PAN with no evidence of 
leukocytoclastic vasculitis. (Costedoat-Chalumeau et al., 2002, Elias et al., 1998, Saadoun et 
al., 2010a) 
6. Diagnosis of HCV- mixed cryoglobulinemia  
6.1 Cryoglobulin detection 
The detection of serum cryoglobulins is fundamental for the diagnosis of mixed 
cryoglobulinemia. (Ferri et al., 2002 a, Ferri et al., 2008) Due to their thermal instability, the 
measurement of cryoglobulin level in the blood should be performed immediately after 
sampling. For a correct evaluation of serum cryoglobulins it is necessary to avoid false-
negative results due to Ig cold precipitation at room temperature, blood sampling, clotting, 
and serum separation by centrifugation is carried out at 37°C and the cryocrit determination 
and cryoglobulin characterization at 4°C (after 7 days). Cryocrit determinations (percentage 
of packed cryoglobulins referred to total serum after centrifugation at +4°C) should be done 
on blood samples without anticoagulation to avoid false-positive results due to cryo-
fibrinogen. The analysis of cryoprecipitates is generally carried out by means of 
immunoelectrophoresis or immunofixation, other more sensitive methodologies include; 
immunoblotting or two-dimensional polyacrylamide gel electrophoresis. Type II MC shows 
a microheterogeneous composition. Type II-III mixed cryoglobulinemia represents an 
intermediate, evolutive state from type III to type II. The absence of detectable serum 
cryoglobulins despite the presence of the clinical syndrome is described to be a transient 
phenomenon due to the wide variability of the percentage of cryoprecipitable immune-
complex during the natural history of the disease or, less frequently, to a switching from 
'benign' B-cell lymphoproliferation to malignant lymphoma. The levels of serum 
cryoglobulins usually do not correlate with the severity and prognosis of the disease. (Ferri 
et al., 2002 a, Ferri et al., 2000)  
6.2 Laboratory tests 
Laboratory workup includes complete blood cell count with evidences of anemia of chronic 
disease, thrombocytopenia or autoimmune hemolytic anemia. Erthrocyte sedimentation rate 
is almost always elevated in all types of vasculitis, but a normal ESR does not rule out 
systemic vasculitis. Blood urea nitrogen, creatinine for renal involvement, proteinuria and 
hematuria on urinalysis, a fresh-spun urine sample should be evaluated for red blood cell 
casts or dysmorphic red cells to diagnose glomerulonephritis. Up to 40 % of patients with 
chronic hepatitis C have normal serum ALT levels, even when tested on multiple occasions. 
(Ferri, 2008, Ghany et al., 2009) 
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6.3 Serological tests 
For the diagnosis of HCV, hepatitis C antibody testing is crucial, regarding the response 
to treatment quantitative assessment of viral load HCV-RT-PCR as well as the viral 
genotyping are important prognostic markers. Sustained negative results for HCV-RT-
PCR with treatment signifies a sustained viral response. Rheumatoid factor and serum 
anti-cyclic citrullinated C peptide antibodies (markers for rheumatoid arthritis)are useful 
diagnostic tools in arthritis patients. Complement 3 (C3) and complement 4 (C4) and 
CH50 are usually consumed in patients with renal disease. Anti-neutrophil cytoplasmic 
antibodies (P-ANCA might be found in patients with small to medium sized vessel 
vasculitis). Anti SSA and anti-SSB (in up to 20%) and thyroid specific antibodies (up t0 
22.1%) are amongst associating serological abnormalities (Ghany et al., 2009, Ferri, 2008, 
Antonelli et al., 2009) 
6.4 Imaging studies  
Chest x ray and high resolution computerized tomography for diagnosis of pulmonary 
involvement, echocardiography and electrocardiogram (ECG) for cardiac disease, 
abdominal ultrasound for hepatic and renal disease. (Ferri, 2008)  
6.5 Biopsy  
Histopathological evidences of vasculitis remain the gold standard for the diagnosis of 
vasculitis. Biopsy from clinically involved sites (cutaneous lesions, nerve biopsy, renal 
biopsy) is a cornerstone in establishing the diagnosis. Bone marrow biopsy should be done 
to demonstrate polyclonal B cell proliferation and in suspected cases with lympho-
proliferative disorders (Mukhtyar et al., 2009).  
6.6 Differential diagnosis 
A frequent clinico-pathological overlap exists between HCV-related cryoglobulinemic 
syndrome and some autoimmune diseases including; small and medium sized vessel 
vasculitides, infectious vasculitides (Bacterial vasculitis e.g., Neisserial, mycobacterial 
vasculitis e.g., Tuberculous, spirochetal vasculitis e.g., Syphilitic, rickettsial vasculitis e.g., 
Rocky Mountain Spotted Fever, fungal vasculitis e.g., Aspergillosis, viral vasculitis e.g., 
Herpes zoster, HIV), primary S-jogren’s syndrome, secondary types of vasculitis 
(rheumatoid arthritis, systemic lupus erythematosus, seronegative arthritides), membranous 
glomerulonephritis, immune mediated thyroiditis, type II diabetes, autoimmune hepatitis, 
and myelo-proliferative disorders (lymphomas, leukemias and Plasma cell dyscrasias). 
(Ghany et al., 2009, Jennette et al., 1994)  
7. Treatment of HCV related vasculitides 
7.1 Treatment of HCV 
Clinical improvement of HCV related vasculitides proved to correlate with virological 
response. Introducing anti-viral therapy namely interferon alpha with or without ribavirin 
remains the cornerstone in the management of HCV-MC. Antiviral therapy has been shown 
to reverse bone marrow monoclonal B-cell expansion in patients with HCV-MC. (Davis et 
al., 2002, Mukhtyar et al., 2009, NIDDK, 2010)  
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Fig. 4. Therapeutic strategies for hepatitis C mixed cryoglobulinemia.  
 
 
Fig. 5. Treatment of HCV cryoglobulinemic renal disease. The management of renal disease 
in HCV mixed cryoglobulinemia depends upon the severity of renal disease.The standard 
regimen is a combination of immunosuppressive drugs, antiviral agents in addition to 
symptomatic therapy. In refractory cases rituximab will be the drug of choice. (Alric et al., 
2004, Kidney International, Guideline 5, 2008) 
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7.1.1 Interferon-alpha therapy 
The standard initial therapy used to be recombinant interferon alfa-2b at a dose of 3 x 106 
units administered subcutaneously 3 times per week for 6 weeks. Recombinant forms of 
alpha interferon are being currently replaced by pegylated interferon (peginterferon). 
Peginterferon is alpha interferon modified chemically by the addition of a large inert 
molecule of polyethylene glycol prolonging its half-life. Peg-Interferon being with better 
efficacy and easier administration replaced standard interferon both as monotherapy and as 
combination therapy for hepatitis C viremia. Peg-interferon is more active than standard 
interferon in inhibiting HCV and yields higher sustained response rates with equivalent side 
effects. Two forms of peg-interferon are available: peg-interferon alfa-2a and peg-interferon 
alfa-2b, roughly equivalent in efficacy and safety, with different dosing regimen. 
Peginterferon alfa-2a is given subcutaneously in a fixed dose of 180 micrograms (mcg) per 
week, while peginterferon alfa-2b is given subcutaneously weekly in a weight-based dose of 
1.5 mcg per kilogram per week in the range of 75 to 150 mcg per week.  
The goal of interferon treatment is suppression of active disease by achieving a sustained 
viral response (sustained decrease or negative HCV-RT PCR). Table 4 Interferon alpha 
monotherapy is effective in purpuric skin lesions, thrombocytopenias, but less effective with 
neural or renal involvement. IFN-alpha monotherapy is associated with a relatively poor 
response and a high virologic relapse rate, detectable viremia with active liver disease can 
occur with normal alanine transferase. Higher initial doses and longer duration of therapy 
help to increase the interval before relapse and escalation of the dose might help to achieve 
response in some non-responders. 
 Peg-interferon therapy has bone marrow suppressive effects or cytopenias, therapy might 
be associated with immune mediated side effects including in about 2% of patients 
(particularly if high titers of antinuclear or antithyroid antibodies); peripheral sensory-
motor neuropathy, nephropathy, retinopathy and micro-hemorrhages, thyroiditis, Sjogren’s 
syndrome, rheumatoid like polyarthritis, psoriasis, fever, chills, headache, lethargy, 
somnolence, myalgia and fatigue, anorexia, hearing loss and tinnitus and serious CNS 
complications might occur during therapy. Rare side effects include; acute congestive heart 
failure, renal failure, vision loss, pulmonary fibrosis or pneumonitis, sepsis, acute 
myocardial infarction, stroke, suicide, and sepsis. Paradoxical worsening of hepatic disease 
provoking a form of autoimmune hepatitis that requires corticosteroid therapy is rare. 
Peginterferon therapy is contraindicated in severe depression or other neuropsychiatric 
syndromes, active substance or alcohol abuse, uncontrolled autoimmune disease (such as 
rheumatoid arthritis, lupus erythematosus, or psoriasis), bone marrow compromise, and 
inability to practice birth control measures. (Casato et al., 1997, Ferri et al., 1993, Iga et al., 
2005, Lidove et al., 1999). 
7.1.2 Ribavirin 
Ribavirin is a broad spectrum antiviral nucleoside analog which acts through enhancement 
of host T-cell–mediated immunity against viral infection through switching the T-cell 
phenotype from type 2 to type 1, inhibition of the host enzyme inosine monophosphate 
dehydrogenase (IMPDH), direct inhibition of HCV, including NS5B-encoded 
RNAdependent RNA polymerase (RdRp) and being an RNA mutagen it drives a rapidly 
mutating RNA virus over the threshold to “error catastrophe”. Ribavirin is an oral drug, 
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given twice a day in 200-mg capsules for a total daily dose based upon body weight (1,000 
mg< 75 kg or 165 pounds and 1,200 mg for those >75 kg). Combination of ribavirin and 
interferon increases the sustained response rate by 2- to 3-fold with rapid improvements in 
serum ALT levels and disappearance of detectable HCV RNA in up to 70 percent of 
patients. The optimal therapeutic dose of ribavirin and the optimal duration varies 
depending upon viral genotype (genotype I, rare genotypes 4, 5, 6 require the maximum 
therapeutic dose/body weight, and longer duration). Considering the variable responses to 
treatment, testing for HCV genotype is clinically useful before starting combination therapy. 
A response is considered “sustained” if HCV RNA remains undetectable for 6 months or 
more after stopping therapy.Some patients relapse by the end of treatment, the relapse rate 
is lower with combination therapy (55% sustained response with combination therapy for 48 
weeks compared 35% with monotherapy) 
 









Calleja et al., 
1999 (13) 
13 Prospective IFN 3 MU × 3 per 
week + Riba 1200 
mg/day × 1 year 
65 22% relapse 
rate 
Zuckerman et 
al., 2000 (114) 
9 Prospective IFN 3 MU × 3 per 
week + Riba 15 
mg/kg/day × 6 
months. 
100 NA 
Donado et al., 
1998 (28) 
17 Prospective IFN 6 MU × 3 per 
week × 3 months,  
3 MU × 3 per week 
× 3 months + Riba 
15 mg/kg/day × 6 
months 
85 55% relapse 
rate within 1 
year 
Mazzaro et 
al., 2003 (68) 
27 Prospective IFN 3 MU × 3 per 
week + Riba 1200 
mg/day × 1 year 






Table 5. Combined Treatment Interferon plus Ribavirin in HCV-related 
Cryoglobulinemia.CR = Complete remission; HCV = Hepatits C virus; NA = Not applicable; 
PR = Partial remission; Riba = Ribavirin. 
Ribavirin therapy causes anemia, fatigue and irritability, itching, skin rash, nasal stuffiness, 
sinusitis, and cough, red cell hemolysis to a variable degree in almost all patients. Patients 
with a pre-existing hemolysis or anemia (hemoglobin < 11 grams or hematocrit < 33 percent) 
should not receive ribavirin. Similarly, patients who have significant coronary or cerebral 
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vascular disease should not receive ribavirin, as the anemia caused by treatment can trigger 
significant ischemia. Fatal myocardial infarctions and strokes are amongst reported side 
effects during combination therapy with alpha interferon and ribavirin. 
Ribavirin is excreted largely by the kidneys. Patients with renal disease can develop 
hemolysis that is severe and even life threatening. With serum creatinine above 2.0 mg per 
deciliter (dL) patients should not be treated with ribavirin. Ribavirin causes birth defects in 
animal studies and should not be used in women or men without contraception. Peg-
interferon has direct antigrowth and anti-proliferative effects so it is contraindicated during 
pregnancy. Combination therapy should therefore be used with caution. Contraindications 
to ribavirin include marked anemia, renal dysfunction, and coronary artery or 
cerebrovascular disease, and inability to practice birth control. The newly emerging direct-
acting antiviral (DAA) drugs are at the preclinical developmental stage and several are in 
clinical development. Initial clinical trials using some of these inhibitors, either alone or in 
combination with pegylated IFN-alpha and ribavirin, have yielded encouraging results. 
(Cacoub et al., 2002, Mazzaro et al., 2003, Pawlotsky, 2011) Table 5. Recently nucleotide 
polymorphism upstream of IL-28B gene has been found to be associated with response to 
PEG-IFN and ribavirin and spontaneous clearance of HCV infection in addition, genetic 
variants of inosine triphosphate (ITPA) have been correlated with protection against 
ribavirin induced hemolytic anemia (Fellay 2010) 
7.2 Corticosteroids, standard Immunosuppression and plasma exchange therapy 
The treatment of cryoglobulinemic vasculitis depends upon the severity of the acute 
manifestations and the extent of organ involvement. In asymptomatic MC monitoring 
without treatment is recommended. In patients with mild to moderate cryoglobulinemic 
symptoms (purpura, arthralgias, peripheral sensory neuropathy) first-line 
immnosuprression usually consists of low-dose corticosteroids. Patients with severe 
manifestations (cryoglobulinemic nephropathy, skin ulcers, sensory motor neuropathy, 
wide spread vasculitis) should promptly receive high-dose steroids and 
immunosuppressive therapy. Use of high dose intravenous corticosteroids might be useful 
for controlling life threatening organ involvement. Immunosuppressive drugs (e.g., 
Cyclophosphamide, Chlorambucil, and Azathioprine) can be used to suppress antibody and 
cryoglobulin production. The most effective and commonly used cytotoxic drug is 
Cyclophosphamide (750-1000mg intravenous pulse or orally at doses of 2 mg/kg per day). 
Recently; Mycophenolate Mofetil (1 g twice a day) is used as an alternative to 
Cyclophosphamide for the induction of remission in MC vasculitis. Mycophenolic Acid is 
more selective than Cyclophosphamide in inhibiting lymphocyte proliferation and 
functions, the drug was found to reduce viremia in HCV-infected renal or heart-transplant 
recipients due to its ability to inhibit inosine monophosphate dehydrogenase, the target 
enzyme inhibited by ribavirin. (Cacoub et al., 2005) 
6.3 Plasma exchange 
Plasma exchange therapy permits rapid control of life threatening symptoms of vasculitis by 
removal of circulating immune complexes with or without using high dose intravenous 
corticosteroids or immunosuppressive treatments, particularly in active cryoglobulinemic 
nephropathy. Oral cyclophosphamide (50-100 mg/day for 2-6 weeks) during the tapering of 
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aphaeretic sessions can reinforce the beneficial effect of plasma exchange; and prevent the 
rebound phenomenon that may be observed after the aphaeresis discontinuation. Plasma 
The use of INF- alpha after each plasma exchange session doesn’t modify the viral response 
(Hausfaster et al., 2002, Khattab et al., 2010, Morra, 2010)  
7.4 Biologic agents 
7.4.1 Anti-CD20 therapy -Rituximab 
Rituximab is a humanized anti- CD-20 monoclonal antibody that was primarily 
successfully employed for the treatment of B-cell lymphomas and other chronic 
lymphoproliferative diseases. The drug has proven efficacy in autoimmune disorders 
including vasculitis and refractory systemic lupus with nephritis. Recently, rituximab 
showed efficacy in cases of HCV-mixed cryoglobulinemia. The drug was successfully 
used in combination with antiviral agents as well as monotherapy in HCV 
cryoglobulinemic vasculitis. Rituximab combined with Peg-IFN-ǂ/ribavirin delete both 
virus-dependent and -independent B-cell clones. Antiviral therapy alone decreased the 
memory B cells; whereas in association with rituximab, naive B cells are the main 
depleted population. This fact accounts for the delayed B-cell reconstitution after 
rituximab plus Peg-IFN-ǂ/ribavirin and stresses the synergistic action of rituximab and 
antiviral therapy at the immunologic level. Rituximab shortens the therapeutic interval 
required for achieving a complete clinical reponse. Clonal expansion of marginal zone–
like IgM+ CD27+ B cells (VH1-69 clonal B) has been recently observed in certain HCV-MC 
patients. Rituximab with Peg-IFN and ribavirin exerts a synergistic effect on polclonal B 
lymphocyte expansion. Rituximab plus Peg-IFN-ǂ/ribavirin was more efficient to 
suppress both memory and VH1-69 clonal B cells compared with Peg-IFN-ǂ/ribavirin 
alone. (Zaga et al., 2003, Sansonno et al., 2003, Roccatello et al., 2008) A standard 
therapeutic dose of 375 mg/m2 weekly for 4 weeks is effective, well tolerated and induces 
a significant and rapid improvement of clinical signs (purpura, arthralgia, peripheral 
neuropathy) with a decline of cryocrit in most patients with mixed cryoglobulinemia even 
in cases resistant to IFN therapy.  
Rituximab trials emphasized the benefit of the drug in inducing remission in cutaneous 
vasculitis, cryoglobulinemic nephropathy, cryoglobulinemic neuropathy and in underlying 
malignant lymphoproliferative disorder. Relapse of cryoglobulinemic vasculitis might 
occur. Complete clinical remission was associated with a significant reduction of RF activity 
and anti-HCV antibody titers. (Saadoun et al., 2008) An increase of viremia might be 
observed in responders, with insignificant variation of transaminases or deterioration of 
liver disease. Rituximab infusions proved effective on cryoglobulinemic vasculitis, with a 
Recent studies showed a relapse in 36.1% of patients within a few days to 19 months after 
the last rituximab infusion. Complete immunologic response was higher with the 
combination of rituximab plus Peg-IFN-ǂ/ribavirin. Recently, rituximab treatment of a 
renal-transplant patient with de novo HCV-related type III cryoglobulinemic MPGN 
resulted in clearance of cryoglobulinemia, a decrease in proteinuria yet without a change in 
serum creatinine or HCV RNA. Rituximab, the drug can cause serum sickness, serum 
sickness like disease, neutropenia and increased risk of infections, pneumopathy, varicella 
zoster infection, erysipelas and as monotherapy increases HCV viremia. (Saadoun et al., 
2010, Pereira et al., 2010) Table 6  
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Table 6. Rituximab treatment in Patients with HCV cryoglobulinemic vascultis.CNI = 
Calcineurin inhibitor; HCV = Hepatitis C virus; HSV = Herpes simplex virus; MMF = 
Mycophenolate mofetil; NR = Not reported; S = Steroids.↑: Increase; ↓: Decrease; =: No 
change. 
7.5 Low antigen diet (LAC-diet) 
LAC-diet is a particular dietetic treatment that can improve the clearance of circulating 
immune-complexes by restoring the activity of the reticulo-endothelial system, overloaded 
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by large amounts of circulating cryoglobulins. LAC-diet can be used for controlling mild 
disease manifestations. (Ferri et al., 1989, Morra, 2010) 
7.6 Symptomatic therapy 
Controlling blood pressure: diuretics, renin–angiotensin system blockade, the treatment of 
hyperlipidemia, are of proven benefit in prognosis of renal disease. Colchicine, an anti-
inflammatory agent has been proposed for MC patients with mild to moderate levels of the 
disease. (Khattab et al., 2010)  
7.7 Treatment of HCV-related vasculitis relapses 
Clinical relapses are usually associated with relapsing HCV viremia (detectable HCV-RT-
PCR). The use of combination therapy for in escalating doses for longer duration (18-24 
months) effective in limiting relapses particularly in cases with renal involvement or 
peripheral neuropathy. A relapsing cryoglobulinemic vasculitis without HCV viral relapse 
might occur and in such conditions the possibility of an underlying malignant lymphoma (B 
cell Non-Hodgkin’s Lymphoma) should be considered. Relapses can be successfully treated 
with a second trial of combination antiviral therapy with immunosuppression or anti CD-20 
monoclonal antibody rituximab. (Fois et al., 2003, Saadoun et al., 2010) New direct acting 
antiviral drug combinations are under trial, the evolution of these drugs might expand the 
therapeutic benefit of combination therapy in HCV infection as well as extrahepatic disease. 
(Franciscus, 2011) 
8. Prognosis 
The prognosis of HCV-MC depends upon the extent and severity of organ involvement and 
the response to treatment (viral load and clinical manifestations). The overall prognosis is 
worse in persons with concomitant renal disease or lympho-proliferative disease (B cell non 
Hodgkin lymphoma or malignant lymphoma). Mean survival is approximately 50% at 10 
years after diagnosis. Survival rates reported among patients with cryoglobulinemic renal 
involvement varies from greater than 60% at 5 years of follow-up, up to 30% at 7 years of 
follow-up. Infection, cardiovascular disease and hepatic failue are amongst causes of 
morbidity. (Morra, 2010, Saadoun et al., 2010) 
9. Conclusion 
Mixed cryoglobulinemia represents a form of leukocytoclastic vasculitis, which is 
considered to be a relatively rare disorder. Given its clinical polymorphism, a correct 
diagnosis might be delayed in addition the actual prevalence of disease is probably 
underestimated. Establishing the diagnosis of HCV-MC requires careful patient 
evaluation, biopsy from involved sites is the gold standard for diagnosing 
leukocytoclastic vasculitis. Owing to its’ complex etio-pathogenesis and clinical 
polymorphism, the treatment of mixed cryoglobulinemia and cryoglobulinemic vasculitis 
remains challenging. The initial therapeutic step must target hepatitis C viremia being the 
chronic trigger for sustained immune-stimulation and autoantibody production. The 
second therapeutic target is to control downstream B cell clonal expansion thereby 
controlling the autoimmune manifestations related to cryoglobulinemia 
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(cryoglobulinemic vasculitis), and management of neoplastic complications. The 
prognosis of the disease depends largely upon the extent and severity of organ 
involvement and adequate therapeutic intervention.  
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